U.S. Markets open in 1 hr 53 mins

Spherix Incorporated (SPEX)

NasdaqCM - NasdaqCM Delayed Price. Currency in USD
Add to watchlist
1.51-0.05 (-3.21%)
At close: 4:00PM EDT
People also watch
MBRXXGTIIDXGHMNYOPXA
Full screen
Previous Close1.56
Open1.52
Bid1.41 x 2200
Ask1.75 x 200
Day's Range1.50 - 1.55
52 Week Range0.83 - 4.75
Volume153,657
Avg. Volume1,648,015
Market Cap9.41M
Beta-1.53
PE Ratio (TTM)-1.00
EPS (TTM)-1.51
Earnings DateN/A
Dividend & Yield0.00 (0.00%)
Ex-Dividend Date1980-05-12
1y Target Est19.00
Trade prices are not sourced from all markets
  • PR Newswire15 days ago

    Hoth Therapeutics Inc. Announces the Addition of Dr. Andrew Herr to the Company's Technology Advisory Board

    NEW YORK, Sept. 5, 2017 /PRNewswire/ -- Hoth Therapeutics Inc., a Nevada corporation ("Hoth" or the "Company"), a development stage biopharmaceutical company focused on unique targeted therapeutics for patients suffering from indications such as atopic dermatitis, also known as eczema, announced today the addition of Dr. Andrew Herr, PhD, to the Company's Technology Advisory Board.  The Technology Advisory Board was formed to assist the Company in developing the BioLexa Platform.  The BioLexa Platform is a proprietary, patented, drug compound platform developed at the University of Cincinnati.

  • Spherix Announces the Addition of Dr. Scott T. Tagawa to Company's Technology Advisory Board
    PR Newswirelast month

    Spherix Announces the Addition of Dr. Scott T. Tagawa to Company's Technology Advisory Board

    NEW YORK, Aug. 15, 2017 /PRNewswire/ -- Spherix Incorporated ("Spherix" or the "Company") (SPEX), an intellectual property development company committed to the fostering of technology, today announced the addition of Dr. Scott T. Tagawa to the Company's Technology Advisory Board.  The Technology Advisory Board was formed to assist the Company in evaluating potential opportunities in the biopharmaceutical arena. Dr. Scott T. Tagawa, MD, MS is the Richard A. Stratton Associate Professor in Hematology and Oncology and an Associate Professor of Clinical Medicine and of Clinical Urology at Weill Cornell Medicine.

  • Spherix Issues Letter to Shareholders
    PR Newswire2 months ago

    Spherix Issues Letter to Shareholders

    NEW YORK, Aug. 2, 2017 /PRNewswire/ -- Spherix Incorporated (SPEX) an intellectual property development company committed to fostering of technology, today issued a letter to shareholders. It is with great pleasure that I take this opportunity to update you on recent events at the Company and describe in greater detail our strategic path forward.   The fundamentals at Spherix are stronger than they have been in recent memory and our path to value creation is moving forward with precision and focus.